An offering of around 1.4 million shares of common stock involving a single health care institutional investor could bring in approximately $2.7 million in gross proceeds, or up to $5.57 million if stock purchase warrants are fully exercised, for Israel-based Check-Cap. Net proceeds will support the ongoing clinical development of the C-Scan ingestible capsule-based system for preparation-free colorectal cancer screening.
Offering could bring in $2.7M for Check-Cap
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.